

THE 23RD SCIENTIFIC MEETING OF THE
INTERNATIONAL SOCIETY OF HYPERTENSION



GLOBAL CARDIOVASCULAR RISK REDUCTION

Vancouver Canada • September 26-30 • 2010

www.vancouverhypertension2010.com

PROGRAM UPDATE

JOINT MEETING FOR THE

ISH 2010 

 Hypertension
CANADA

This Program Update contains the updates and corrections to the ISH Scientific Program that have occurred since the printing of the Final Program. It also contains the Speaker Disclosure information.

The updates and corrections are listed by day. The *Page Number* references the session or poster's page number location in the Final Program.

MONDAY, SEPTEMBER 27

Scientific Program Concurrent Sessions

New presentation added at 8:45, presentation times changed

Page in Final Program: 53

- 08:15-09:45** **Public Health – Population Science**
Plenary Symposium
Uncontrolled Hypertension
– A Global Health Issue Ballroom A, L1
- 08:15** **Incidence and Prevalence of Hypertension in**
Canada, from 1998/99 to 2006/07
Robitaille C, Canada
- 08:25** **Hypertension Prevalence in Malaysia**
Yusoff K, Malaysia
- 08:35** **Prevalence of Uncontrolled Hypertension in South**
America
Juncos L, Argentina
- 08:45** **Hypertension in Africa**
Lemogoum D, Cameroon
- 08:55** **The Perspective from China**
Zhao D, China
- 09:15** **Hypertension in Developed Countries**
Poulter NR, United Kingdom

Co-chair added (Lee MM)

Page in Final Program: 53

- 08:15-09:45** **Clinical Science**
State of the Art – Oral Presentations
Hypertension-related Cardiovascular
Complications: Predictors of Risk and
Responses to Therapy Ballroom B, L1

Chairs: Meredith PA, United Kingdom, Lee MM, Korea,
Republic of

MONDAY, SEPTEMBER 27

Scientific Program Concurrent Sessions

Chair added

Page in Final Program: 57

10:30-12:00 **Public Health – Population Science Symposium**
Formulating Cardiovascular Public Policy Ballroom A, L1

Chair: Young ER, Canada

New presenter (replacing Butler-Jones D, Canada)

Page in Final Program: 57

10:30-12:00 **Public Health – Population Science Symposium**
Formulating Cardiovascular Public Policy Ballroom A, L1

11:30 **Formulating Health Policy for Cardiovascular Health – A Canadian Perspective**
Elmslie K, Canada

New presenters

Page in Final Program: 64

14:15-15:45 **Clinical Science Debates**
Clinical Science – Debate 1 Room 109-110, L1

14:15 **Should Masked Hypertension be Treated?**
Pro: McKay D, Canada
Con: Parati G, Italy

15:00 **Are the Antihypertensive/CV Risk Reducing Effects of Diuretics a Class (or a Chlothaldione-Specific) Effect?**
Pro: Poulter NR, United Kingdon
Con: MacFarlane P, Canada

MONDAY, SEPTEMBER 27

Scientific Program Concurrent Sessions

Presentation removed and a new presentation added to session as a replacement

Page in Final Program: 66/67

16:30-18:00

Basic Science

State of the Art – Oral Presentations

Vascular Signaling

Room 211-214, L2

17:20

Uncoupling Protein 2 Ablation Exacerbates High Salt Intake-Induced Vascular Dysfunction

Ma S¹, Ma L¹, Yang D¹, Hao X¹, Liu D¹, Zhu Z¹
¹China

Above Presentation is withdrawn and will be replaced by the following presentation (**PS2/TUE/47**) (pg. 112 in Final Program):

Salt Causes Cardiovascular Damage Dose-Dependently, but Independently of Its Effect on Blood Pressure in General Population

Hagikura A¹, Takase H¹, Toriyama T¹, Okado T¹, Sonoda H¹, Dohi Y¹, Kimura G¹
¹Japan

Poster Sessions

The following poster presentations have been withdrawn:

Poster Session A

PS1/MON/2 – pg. 68

PS1/MON/3 – pg. 68

TUESDAY, SEPTEMBER 28

Scientific Program Concurrent Sessions

Presenter change

Page in Final Program: 91/92

08:15-09:45 **Clinical – Population Science
Symposium**
**Optimal Guidelines for Management
of Hypertension** Ballroom A, L1

09:15 **ISH/WHO Guidelines Why is it Different and Why is
There a Need for it**
Mendis S, Switzerland

New presenter

Page in Final Program: 99

14:15-15:45 **Clinical – Population Science
Symposium**
**Dietary Approaches in Management
of Cardiovascular Risk** Ballroom A, L1

14:45 **Diet and Cardiovascular Disease**
Fodor G, Canada

Poster Sessions

The following poster presentations have been withdrawn or moved:

Poster Session B

PS2/TUE/38 – moved to oral – pg. 111

PS2/TUE/47 – moved to oral – pg. 112

PS2/TUE/50 – pg. 113

PS2/TUE/211 – pg. 135

PS2/TUE/213 – pg. 136

PS2/TUE/286 – moved to oral – pg. 146

PS2/TUE/288 – pg. 146

TUESDAY, SEPTEMBER 28

Award Session

New session

Page in Final Program: 330

14:15-15:45

ISH Pfizer Award Presentation

Room 220-222, L2

Judges

Chair: S Harrap

Members: R. Hegele, S. Oparil, E. Schiffrin, R. Touyz

Shortlisted Abstracts:

Expression of the Novel Adipokines CTRP (Complement-C1q TNF -related protein)-5, CTRP-6, and CTRP-7 in the Adrenal Gland and Periadrenal Fat Tissue

Rossi GR, Italy

Effects of Hypolipemic Drugs on Modulation of MCP-1, PAI-1 and Adiponectin in 3T3-L1 Adipocytes

Zanella MT, Brazil

Activation of Macrophages is Crucial for the Loss of Anticontractile Capacity of Perivascular Fat Following Inflammation and Can Be Rescued by Eplerenone

Withers S, United Kingdom

Rosuvastatin and Chronotherapy: Effects on Blood Pressure in Hypertensive Subjects with Dyslipidemia

Pena Seijo M, Spain

Plasma Copeptin, a Unifying Factor Behind the Metabolic Syndrome

Enhörning S, Sweden

Natriuretic Peptides/ cGMP-dependent Protein Kinase Cascades Increase Muscle Mitochondrial Content and Prevent Obesity

Miyashita K, Japan

WEDNESDAY, SEPTEMBER 29

Scientific Program Concurrent Sessions

Chair added

Page in Final Program: 152

08:15-09:45 **Basic – Translational Science
Symposium**
Hypertension and the Kidney Room 211-214, L2
Sponsored by the International Society of
Nephrology

Chair: Larivière R, Canada

New presenter and presentation title change

Page in Final Program: 152

08:15-09:45 **Translational – Clinical Science
Symposium**
**Unravelling the Genetics of Hypertension
and Vascular Disease** Ballroom C, L1

08:45 **Genetics of Hypertension – Molecular Mechanisms
in the Vasculature**
Sigmund CD, United States

Change of presenter

Page in Final Program: 158

10:30-12:00 **Clinical – Population Science
Symposium**
**Prevention of Cardiovascular
Disease with Worksite/Community
Based Programs** Room 109-110, L1

10:30 **Cardiovascular Risk Reduction at the Workplace:
The Israeli Experience**
Gavish D, Israel

WEDNESDAY, SEPTEMBER 29

Scientific Program Concurrent Sessions

Co-chair added (Insel P)

Page in Final Program: 154

10:30-12:00

Basic Science

Symposium

GPCR Signalling: Dysregulation in Hypertension – A Tribute to Jacques de Champlain

Ballroom A, L1

Chairs: Moreau P, Canada, Insel P, United States

Co-chair added (Aviv A)

Page in Final Program: 157

10:30-12:00

Translational – Clinical Science

State of the Art – Oral Presentations

Vascular Aging

Room 211-214, L2

Chairs: Pickering G, Canada, Aviv A, United States

Poster presentations added as oral presentation

Page in Final Program: 160

14:15-15:45

Translational – Clinical Science

Symposium

Hypertension and Pregnancy

Room 211-214, L2

15:15-15:30

Prediction of Preeclampsia by First Trimester E-Selectin

Dellec C, United Kingdom

15:30-15:45

Vitamin D and Hypertension in Pregnancy

Ringrose J, Canada

WEDNESDAY, SEPTEMBER 29

Poster Sessions

Presenter change

Page in Final Program: 166

PS3/WED/9

Class Effects of BP-Lowering Drugs on Central Blood Pressure Measurement

Uetani E¹, Tabara Y¹, Igase M¹, Kido T¹, Ochi N¹, Kohara K¹, Miki T¹
¹Japan

Presentation title change

Page in Final Program: 167

PS3/WED/18

Damage to the Anticontractile Capacity of Perivascular Adipose Tissue Strongly Correlates with Elevation of Blood Pressure: Results from a Diet-Induced Model of Obesity

Park BH¹, Aghamohammadzadeh R¹, Greenstein AS¹, Porter EL¹, Edwards G¹, Weston AH¹, Heagerty AM¹
¹United Kingdom

Presenter change

Page in Final Program: 169

PS3/WED/31

The G Protein Regulator Phosducin Influences the Risk of Hypertension Only in Patients with Overweight

Ragazzo F¹, Ceolotto G¹, Frigo G¹, Bratti P¹, Saladini F¹, Santonastaso M¹, Mos L¹, Cozzio S¹, Palatini P¹
¹Italy

Presenter change

Page in Final Program: 179

PS3/WED/106

Postprandial Hypotension as a Risk Factor for Cognitive Decline in Community-Dwelling Elderly Persons

Uetani E¹, Tabara Y¹, Igase M¹, Kido T¹, Ochi N¹, Yamamoto M¹, Kohara K¹, Miki T¹
¹Japan

WEDNESDAY, SEPTEMBER 29

Poster Sessions

Presenter change

Page in Final Program: 186

PS3/WED/152

Combination of Telmisartan 80 MG and Hydrochlorothiazide 25 MG Provides Clinically Relevant Blood Pressure Reductions in Hypertensive Patients Irrespective of Baseline Blood Pressure

McGill J¹, Neldam S², Schumacher H³, Guthrie R¹

¹United States, ²Denmark, ³Germany

New presenter

Page in Final Program: 187

PS3/WED/157

Baroreflex Activation Therapy® (BAT®) Acutely Improves Central Arterial Properties in Resistant Hypertension Patients

Heusser K¹, Tank J¹, Engeli S¹, Menne J¹, Eckert S¹, Haller H¹, Georgakopoulos D², Pichlmaier AM¹, Luft FC¹, Jordan J¹, Kaufman C.²

¹Germany, ²United States

Presenter change

Page in Final Program: 187

PS3/WED/158

Baroreflex Activation Therapy® Improves Functional Capacity and Reduces Left Ventricular Mass Index: Results From European and United States Trials of the Rheos® System

Bisognano JD¹, Kroon AA², Bach DS¹, Kaufman C¹, de Leeuw P²

¹United States, ²Netherlands

Presenter change

Page in Final Program: 205

PS3/WED/284

Intimal Thickening in the Leg Arteries as an Early Indicator of Atherosclerosis in Hypertensive Patients

Agarwal SK¹, Agarwal NK¹

¹United States

WEDNESDAY, SEPTEMBER 29

Poster Sessions

New Presenter

Page in Final Program: 219

PS3/WED/388

Urinary Calcium and Magnesium Excretion and Blood Pressure: INTERMAP Study

Tzoulaki I¹, Kesteloot H², Brown IJ¹, Stamler J³, Elliott P¹, Wijeyesekera A¹,
International Collaborative Research Group on Macro-/Micronutrients and
Blood Pressure

¹United Kingdom, ²Belgium, ³United States

The following poster presentations have been withdrawn:

PS3/WED/4 – pg. 165

PS3/WED/43 – pg. 170

PS3/WED/53 – pg. 172

PS3/WED/265 – pg. 202

PS3/WED/266 – pg. 202

PS3/WED/309 – pg. 208

PS3/WED/355 – pg. 214

THURSDAY, SEPTEMBER 30

Scientific Program Concurrent Sessions

Presentation title change

Page in Final Program: 227

08:15-09:45 **Public Health – Population Science**
State of the Art – Oral Presentations
Chronic Disease Prevention Ballroom B, L1

08:15 **Update on the Sodium Reduction Strategy for Canada**
Hutchinson H, Canada

Presentation removed, new speaker and presentation title change

Page in Final Program: 231

10:30-12:00 **Clinical Science**
Symposium
Mechanisms of Obesity and
Obesity-Related Cardiometabolic
Complications: Emphasis on
Children and Adolescence Ballroom A, L1

Chair: Touyz R, Canada

10:30 **Pathophysiologic Mechanisms Linking Obesity and Hypertension: The Role of Vascular Fat in the Interaction of Obesity and Hypertension**
Heagerty AM, United Kingdom

11:00 **Impact of Obesity on Blood Pressure in Children and Adolescents**
Stabouli S, Greece

11:30 **Stemming the Tide of Obesity: Management of Obesity in Children and Adolescents**
Chanoine JP, Canada

THURSDAY, SEPTEMBER 30

Scientific Program Concurrent Sessions

Session withdrawn

- 10:30-12:00 **Clinical Science**
Symposium
Mechanisms of Obesity and
Obesity-Related Cardiometabolic
Complications Ballroom A, L1
- 10:30 **Pathophysiologic Mechanisms Linking Obesity and**
Hypertension
Hall J, United States

Session withdrawn

Page in Final Program: 238

- 14:30-15:20 **Population Science**
Late Breaker Presentations
Population Featured Research Ballroom B, L1
- 14:40 **Risk of Hypertension in Rural Outpatient**
Population of Anhui Province, P.R. China
Hu S-Li, Wu Li, Fang Xi, Chen Yi, Shen Gi
1China

Co-chair added (Onrot J)

Page in Final Program: 238

- 14:30-15:20 **Population Science**
Late Breaker Presentations
Population Featured Research Ballroom B, L1
- Chairs:** Chockalingam A, Canada, Onrot J, Canada

THURSDAY, SEPTEMBER 30

Scientific Program Concurrent Sessions

New session

- 14:30-15:30 **Clinical Science**
Late Breaker Presentations
Do ARBs Cause Cancer? Ballroom A, L1

Chair: Elliot H, United Kingdom

Do Angiotensin Receptors Blockers (ARBs) Cause Cancer
- 14:30 Background on the Potential for Drugs to Cause (Lung) Cancer
McWilliams A, Canada
- 14:40 The Evidence in Favour of ARBs Producing Cancer
Campbell N, Canada
- 15:00 The Evidence Against ARBs Producing Cancer
Julius S, United States
- 15:20 Discussion

Poster Sessions

Oral session to poster PS4/THU/287

- 15:30-16:30 **Basic Science**
Late Breaker Presentations
Late Breaking Studies
Pathobiology Ballroom C, L1
- 15:30 Inhibition of Apop Gene Expression Prevents Hypoxia/reoxygenation-Induced Death of Cardiomyocytes
Yamamoto E¹, Yasuda O¹, Mitsuyama SK¹, Ogawa H¹
¹Japan

THURSDAY, SEPTEMBER 30

Poster Sessions

Presentation title change

Page in Final Program: 257

PS4/THU/101

Interaction between Sleep Duration and Genetic Variations in Development of Hypertension: A 6 Year of Follow-Up in Korean Genome Epidemiology Study (KoGES)

Lee SK¹, Baik I¹, Kim SH¹, Kim S¹, Lee J¹, Cho N¹, Han B-G¹, Chol S¹

¹Korea, Republic of

Presenter change

Page in Final Program: 265

PS4/THU/159

Metabolic Syndrome Prevalence in Arterial Hypertension Unit of Granada (South of Spain)

Mediavilla García JD¹, Jaén Águila F¹, Fernández Torres C¹, Jiménez Alonso J¹

¹Spain

The following poster presentation has been withdrawn:

PS4/THU/161 – pg. 265

SPEAKER DISCLOSURE

In accordance with Accreditation Council of Continuing Medical Education (ACCME) Standards for Commercial Support, all faculty participating in these programs are expected to disclose to the program audiences any real or apparent conflict of interest related to the content of their presentation.

Name	Do you have any relationship(s) with any pharmaceutical and/or corporate sponsors in relation to the presentation of your subject that need to be disclosed? If yes, please describe below.
Michael Adams	Grant funding from Amgen Inc. regarding treatments for chronic kidney disease related outcomes
Lawrence J. Appel	Honorarium from Unilever
Malcolm Arnold	No response
Abraham Aviv	None
Simon Bacon	Paid consultant for CME on health behaviour change, Merrck Frost; Advisory board for obesity-asthma study, Scherring-Plough
George Bakris	Consultant for Merck, Novartis, GSK, Fibrogen, Johnson and Johnson, Walgreen's, Daiichi-Sankyo, Takeda, Abbott. Investigator-initiated grants: GSK, Forest
Susan Barr	Member of Health Canada's Food Guide Advisory Committee, 2004-2007 (no remuneration)
Peter Bolli	None
Steffen-Sebastian Bolz	None
Michel Bouvier	None
Nancy Brown	Consultant for Novartis, Merck, Boehringer-Ingelheim; Grant funding Forest Pharma and Shire HRT
Christopher Bulpitt	In receipt of research funds and honoraria from Institut de Recherches Internationales Servier
David Butler-Jones	None
Norman Campbell	Support for travel to meeting, 2010 BI
Tavis Campbell	None
Marc Caron	No response
Lisa A. Cassis	None
John Chalmers	Received Research grants from Servier International, as Co-PI for ADVANCE, administered through the University of Sydney; Received Honoraria from Servier for speaking about ADVANCE at Scientific meetings; Member of the Servier Diabetes Advisory Board
Juliana C. N. Chan	Received research grants, consultancy fees and speaker's fee from Astra Zeneca, Bayer, BMS, Daiichi Sankyo, Lilly, Novartis, Novo Nordisk, Merck, MSD, Roche, Sanofi-Aventis and Pfizer on subjects related to diabetes. All proceeds have been donated to the Chinese University of Hong Kong to support ongoing research and education programs in diabetes and related areas
Jean-Pierre Chanoine	Received speaker fees from Roche pharmaceutical company; Participated in a clinical study sponsored by Roche pharmaceutical company
Arun Chockalingam	None
Lyne Cloutier	No response
Thomas Coffman	No response
William Cushman	No response
Cheryl Dennison	None
Murray Esler	Ardian Corporation USA
Majid Ezzati	None
Robert Fagard	None
Ross Feldman	No response
Walter Fischli	No response
John Floras	Vice Chair of a randomized controlled trial evaluating the impact of adaptive servo-ventilation on survival and hospitalizations of heart failure patients who also have sleep apnea. This trial is funded by the Canadian Institutes of Health Research but is supported as well by an unrestricted gift to the Toronto Rehabilitation Institute by Philips Respironics

SPEAKER DISCLOSURE

George Fodor	Research grants from Solvay and Boehringer Ingelheim; Speaker Fees from Solvay
Toshiro Fujita	Honorarium and consulting fees: Takeda, Daiiti-Sankyo, Asteras, Tanabe-Mitsubishi, Novartis, Boehringer, Banyu, and Mochida; Research grants: Takeda, Daiichi-Sankyo, Asteras, Novartis, Boehringer, Banyu, and Tanabe-mitsubishi
John Funder	Consultant to Pfizer, Merck, Fresenius Kabi, Roche; CBio - Board Member
Valentin Fuster	No response
Venkat Gopalakrishnan	None
Beverly Green	None
Robert Gros	None
Steven Grover	Have received research funding from Merck, Bayer, and AstraZeneca; Have been a speaker at symposia sponsored by Merck; Have been a member of advisory boards for Merck, Pfizer, Bayer, BMS, and AstraZeneca
Jong-Won Ha	None
Steven Haffner	Novartis-Navigator Study Executive Committee
John Hall	None
Pavel Hamet	Research grant from Canada Research Chair, Génome Québec / Canada, Pfizer, Pari-GC, Canadian Foundation for Innovation, Canadian Institutes for Health Research; Speaker fees from Merck Frosst, Bristol Myers Squibb, Servier, Novartis, Bayer, Sanofi Aventis, Astra Zeneca; Member of Advisory Board of Pfizer, Bristol Myers Squibb, Eli Lilly, Servier, Novartis, BioK+ and Cybiocare; Consultant for Bellus Health and Servier
Stephen Harrap	None
Michael Hayden	None
A M Heagerty	None
Robert Hegele	None
Michael Hill	CHEP CRC committee; Grant support in the last 5 years from Merck Canada, Bayer Canada, Roche Canada; CIHR grants on hypertension; CSN best practices committee for hypertension guidelines; Honouraria from Sanofi-Aventis, Genentech, Roche Canada, BMS Canada, Portola Therapeutics, Boehringer Ingelheim Canada, Novonordisk Canada
Masatsugu Horiuchi	None
Paul Insel	None
Stevo Julius	None
Janusz Kaczorowski	None
Ananth Karumanchi	No response
Vasilios Kotsis	None
Darwin Labarthe	None
Edward Lakatta	None
Pierre Laroche	Member of advisory boards; Industrial-supported research; Speak at commercially sponsored CHE events
Scott Lear	None
L M Fredrik Leeb-Lundberg	None
Frans Leenen	None
Lawrence Leiter	Received research funding from, have provided CME on behalf of, and have acted as an advisor to Astra Zeneca, BMS, Eli Lilly, GSK, Merck, Novartis, Novo Nordisk, Roche, Sanofi-Aventis and Servier
Dan Levy	No response
Lars Lindholm	None
Lisheng Liu	None
Graham MacGregor	None
Laura Magee	None
Phil McFarlane	No response
Donald McKay	None
Shanthi Mendis	None
Albert Mimran	None
Martin Myers	Consultant to Novartis as part of the role as a co-investigator of the study

SPEAKER DISCLOSURE

Bruce Neal	Consultant/Advisor/Consultant Fee, paid advisory boards or fees for attending a meeting – Pfizer (2005), Roche (2009), Takeda (2010), Pepsico (2010); Lecture fees (honoraria) travel fees or reimbursements when speaking at the invitation of a commercial entity – Amgen (2007), AstraZeneca (2010), GlaxoSmithKline (2007), Pfizer (2007), Roche (2005), Sanofi Aventis (2006), Servier (2008), Tanabe (2007); Research support from a commercial entity – Johnson and Johnson (2010), Merck Schering Plough (2010), Servier (2010), United Healthcare Group (2010); Any other non-financial roles that might be viewed as creating a potential conflict of interest – Professor Neal interacts regularly with multiple large corporations in the Pharmaceutical Industry, the Food Processing Industry and the Quick Service Restaurant industry in Australia and overseas, in his efforts to achieve negotiated solutions to major public health problems
Toshio Ogihara	None
Stefano Omboni	Scientific consultant for the Company developing the telemedicine service used in the Italian Registry
Susan Oparil	Grant Support: Daiichi Sankyo Inc., Gilead, and Takeda; Consultant: Boehringer-Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Forest Laboratories, NicOx, Novartis, Schering-Plough, The Salt Institute, and VIVUS; Honoraria: Daiichi Sankyo Inc., Merck and Co., and Novartis
Eduardo Ortiz	No response
Gary K. Owens	None
Catherine Pang	None
Gianfranco Parati	No response
Steven Pelech	President and Chief Scientific Officer of Kinexus Bioinformatics Corporation. Presentation will include a description of the technologies that are applied at Kinexus to generate some of the information presented in presentation.
Geoffrey Pickering	Presenter holds a patent related to the presentation topic
Andrew Pipe	Pfizer – Research Support; Consultant for Speakers’ Bureau, GSK, Johnson & Johnson
Neil R. Poulter	No response
Simon Rabkin	No response
Robert Roberts	None
Bernardo Rodríguez-Iturbe	No response
Luis M. Ruilope	Advisor and speaker for Lacer, sponsor of Spanish ABPM registry
Ernesto L. Schiffrin	None
Arno Schmidt-Trucksäss	Imedos Systems
Yackoob Seedat	None
William Semchuk	None
Arya Sharma	No response
Kazuaki Shimamoto	Takada Pharmaceutical Company, Novartis Pharma Company, Asteras Pharmaceutical Company
Denise Simons-Morton	None
John David Spence	None
Sarah Spiegel	None
Ann Thompson	None
Jens Titze	None
Sheldon Tobe	No response
Rhian Touyz	None
Raymond Townsend	None
Luc Trudeau	None
Thomas Unger	None
Markus van der Giet	None
Jim Vanderwal	None
J.Reuven Viskoper	None
Peter von Dadelszen	No response
Thomas W. Wilson	None
Xin Hua Zhang	None
Dong Zhao	None

Meeting Secretariat

Contact the Meeting Secretariat (Sea to Sky Meeting Management) at the VCC by visiting the Registration Desk located in the Foyer, West Level 1.

Alternatively, you can contact the Secretariat via email at info@vancouverhypertension2010.com.